Latest Research And Development News

Island Pharmaceuticals is accelerating development of its broad-spectrum antiviral Galidesivir, progressing clinical, regulatory, and manufacturing milestones under the FDA Animal Rule pathway with expanded USAMRIID collaboration and biodefence positioning.

Island Pharmaceuticals has expanded its partnership with USAMRIID to conduct a pivotal Galidesivir dose optimisation study against Marburg virus, targeting topline results in the second half of 2026.

Boresight Ltd (ASX: BST) is seeking to raise $8 million through a public offer to expand its cost-effective military drone manufacturing, targeting growth in the US and European markets.

Elixir Energy has kicked off the stimulation and testing phase at its Lorelle-3H appraisal well, aiming to validate commercial gas and condensate flow rates from Queensland’s Taroom Trough basin-centred gas play.

Aurora Labs has landed a $1 million Australian Government grant, matched dollar-for-dollar, to boost production of its micro gas turbine propulsion systems for defence applications using commercial 3D printing technology.

Amplia Therapeutics reported encouraging mature data from its ACCENT pancreatic cancer trial showing improved survival and response rates with narmafotinib. The company raised $27.5 million to fund development and manufacturing scale-up, while discontinuing a parallel trial due to chemotherapy toxicity.

TradeWindow reported a 20% rise in FY26 revenue to NZ$9.6 million with annual recurring revenue surpassing NZ$10 million. The company narrowed its EBITDA loss and is targeting breakeven in FY27 while advancing its AI-driven FreightAI platform.

Pure Resources (ASX: PR1) has closed a $3 million placement, issuing 12 million shares after shareholder approval, while also issuing options and advisory shares to support exploration and cutting-edge carbon nanotube fibre research.

Phoslock Environmental Technologies reported a sales recovery in 2025 with further growth expected, backed by resumed production in China and promising European projects, while ongoing litigation clouds the outlook.

Ainsworth Game Technology posted a 10% revenue increase in FY25 to $291 million, driven by strong Asia Pacific growth, while North American challenges weigh on H1 2026 outlook.

CleanSpace Holdings expects modest revenue growth for FY26, hindered by product certification delays and global market challenges, while maintaining a strong cash position and preparing a new respirator launch.

Fisher & Paykel Healthcare posted a 14% revenue increase to NZ$2.31 billion and a 24% rise in net profit to NZ$468.5 million for FY2026, driven by strong hospital product sales and ongoing innovation.